Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
成人和青少年慢性特發性蕁麻疹患者中利格利珠單抗的療效和安全性:兩項3期隨機對照試驗結果。
Lancet 2024-04-05
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Bimekizumab在中重度汗腺炎擴散性性膿瘡患者中的療效和安全性(BE HEARD I和BE HEARD II):兩項48週、隨機、雙盲、安慰劑對照、多中心3期試驗。
Lancet 2024-05-25
兩個第三階段試驗 BE HEARD I 和 II 證實 bimekizumab 對中重度汗腺炎患者有效且安全。與安慰劑相比,bimekizumab 顯著改善患者症狀,且應答率更高,持續至48週。不良事件輕微,無新安全問題。bimekizumab 耐受性佳,臨床效果顯著,適合治療汗腺炎患者。
PubMedDOI
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
1 到 11 歲患者中 Dupilumab 用於嗜酸性食道炎。
N Engl J Med 2024-06-26
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
delgocitinib 乳膏在中度至重度慢性手部濕疹成人中的療效與安全性(DELTA 1 和 DELTA 2):來自多中心、隨機、對照、雙盲、第三期試驗的結果。
Lancet 2024-07-21
The efficacy and safety of difelikefalin for pruritus in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials.
Difelikefalin 在血液透析患者瘙癢的療效與安全性:隨機對照試驗的系統評價與統合分析。
Ren Fail 2024-08-02
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
每年兩次使用 Depemokimab 治療具有嗜酸性表現的重度哮喘。
N Engl J Med 2024-09-09
Depemokimab是一種針對白介素-5的長效生物治療藥物,專為重度哮喘及高嗜酸性白血球計數的患者設計。在第三期臨床試驗中,接受depemokimab的患者在52週內的哮喘惡化年化率顯著低於安慰劑組(SWIFT-1: 0.46 vs. 1.11; SWIFT-2: 0.56 vs. 1.08),顯示出強烈的治療效果(P<0.001)。不過,次要結果如聖喬治呼吸問卷得分並無顯著差異,且兩組的不良事件報告相似。總體而言,depemokimab在減少患者惡化方面顯示療效。此研究由GSK資助,並已在ClinicalTrials.gov註冊。
PubMedDOI